Glaukos Corp Stock Price, News & Analysis

Glaukos (NYSE: GKOS) announced positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform. In a 36-month follow-up analysis of Phase 3 trials, iDose TR demonstrated sustained IOP reductions with approximately 70% of subjects remaining well-controlled, compared to 58% of timolol control subjects.

The company has initiated a Phase 2b/3 clinical program for iDose TREX, its next-generation therapy with nearly twice the drug capacity. A 6-month Phase 4 study showed iDose TR combined with cataract surgery achieved a mean IOP reduction of 11.3 mmHg (44%) in open-angle glaucoma patients.

The iDose platform is designed to address patient non-adherence and side effects associated with topical medications by providing 24/7, long-duration efficacy with minimal side effects.

Glaukos (NYSE: GKOS) has submitted a New Drug Application (NDA) to the FDA for Epioxa™, a next-generation corneal cross-linking therapy for keratoconus treatment. The therapy is designed to be the first FDA-approved, non-invasive treatment that preserves the corneal epithelium. The NDA submission includes successful data from two Phase 3 pivotal trials showing favorable efficacy, tolerability, and safety profiles.

Epioxa features a proprietary drug formulation designed to penetrate the epithelium, utilizing stronger UV-A irradiation and supplemental oxygen to enhance cross-linking. The therapy aims to reduce procedure times, improve patient comfort, and shorten recovery time compared to conventional treatments. Keratoconus affects approximately 90% of cases bilaterally, with up to 20% of patients requiring corneal transplants if left untreated.

Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for glaucoma, corneal disorders and retinal diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco. A live and archived webcast will be accessible through the Investors section of the Glaukos website.

Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology, has announced its participation in five major investor conferences in late 2024. The schedule includes appearances at the Stifel Healthcare Conference (Nov 19), Stephens Annual Investment Conference (Nov 20), BTIG Ophthalmology Day (Dec 2), Piper Sandler Annual Healthcare Conference (Dec 4), and Citi Global Healthcare Conference (Dec 5). Live and archived webcasts of these events will be accessible through the company's investor relations website.

Glaukos (NYSE: GKOS) reported strong Q3 2024 financial results with record net sales of $96.7 million, up 24% year-over-year. Glaucoma segment achieved record sales of $76.0 million (+30%), while Corneal Health sales reached $20.6 million (+5%). The company maintained a robust gross margin of 77% (82% non-GAAP) and raised its 2024 net sales guidance to $377-379 million. Despite revenue growth, Glaukos reported a net loss of $21.4 million ($0.39 per share), though improved from $30.4 million loss year-over-year. The company ended Q3 with approximately $267.2 million in cash and investments.

Glaukos (NYSE: GKOS) announced positive topline results from its Phase 3 confirmatory trial for Epioxa™, a next-generation corneal cross-linking therapy for keratoconus. The trial met its primary efficacy endpoint, demonstrating a clinically relevant and statistically significant improvement in maximum corneal curvature (Kmax) at 12 months. Key findings include:

1. A Kmax treatment effect of –1.0 diopter (p <0.0001)
2. 91.5% of treated patients completed the 12-month trial
3. No treatment-related serious adverse events reported
4. No evidence of systemic effects or changes in corneal endothelial cell counts

Glaukos plans to submit a New Drug Application (NDA) to the FDA by the end of 2024. If approved, Epioxa could become the first FDA-approved, non-invasive drug therapy for keratoconus that preserves the corneal epithelium.

Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, announced its participation in the American Academy of Ophthalmology (AAO) annual meeting from October 18-21, 2024, in Chicago. The company will showcase its technologies through scientific presentations and exhibit at booth #2608.

Glaukos is sponsoring an educational symposium titled 'iDose® TR: The Gateway to Interventional Glaucoma' on October 19, 2024. Key glaucoma posters will cover topics such as the effect of travoprost intracameral implant in eyes with prior failed selective laser trabeculoplasty, and long-term outcomes of trabecular micro-bypass stents with cataract surgery in POAG.

The event will also feature corneal health presentations, including a discussion on risk factors for complications after CXL for KCN. The AAO Annual Meeting is a significant gathering for ophthalmic professionals and industry executives.

Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, has announced plans to release its third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company will host a conference call and simultaneous webcast to discuss the results at 1:30 p.m. PT (4:30 p.m. ET) on the same day.

Interested parties can access the live webcast through the company's investor relations website. To participate in the conference call, attendees should dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay of the call will be made available on the company's website following the event's conclusion.

Glaukos (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company, has announced its participation in two upcoming investor conferences. The company, which specializes in novel therapies for glaucoma, corneal disorders, and retinal diseases, will be present at:

1. The Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 12:45 p.m. ET in Boston, MA.

2. The Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 12:20 p.m. ET in New York City, NY.

Glaukos has confirmed that live and archived webcasts of these events, where applicable, will be accessible through the Investors section of their official website at http://investors.glaukos.com.